Astria Therapeutics Inc to Discuss the OX40 Program STAR-0310 Call Transcript
Good morning. And welcome to the Astria Therapeutics webinar. (Operator Instructions) As a reminder, this call is being recorded. And a replay will be made available on the Astria Therapeutics website following the conclusion of the event. I would now like to turn the call over to your host, Elizabeth Higgins with Astria Therapeutics. Please go ahead.
Thank you, Sara. Welcome to today's Astria Therapeutics STAR-0310 conference call. With me today are Jill Milne, Chief Executive Officer; Christopher Morabito, Chief Medical Officer; Andrea Matthews, Chief Business Officer; Andrew Komjathy, Chief Commercial Officer; and available for questions, Noah Clouser, Chief Financial Officer.
We issued a press release yesterday announcing that we have entered into an exclusive worldwide license agreement with Ichnos Sciences for an OX40 portfolio to be developed for the treatment of atopic dermatitis. The press release is available on our website. We are also using slides during today's
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |